Thank you for your interest in the Medtronic Catheter-Based Aortic Valve Replacement Program!

We are excited about our recent acquisitions of CoreValve Inc., developer of the ReValving® System for transfemoral aortic valve replacement, and Ventor Technologies, developer of the minimally-invasive, transapical Embracer™ aortic valve replacement system currently under clinical investigation in Europe.

We believe that by offering complementary catheter-based systems, transfemoral and transapical, we will be best positioned to provide you with the tools necessary to address the individual needs of patients with aortic stenosis and who are at either high or prohibitive risk for surgery.

If you are interested in exploring the future of catheter-based valve replacement therapies with Medtronic, please complete the information request below.

Participation Information

Fill out the information below.

* Required questions must be answered

*Name:
Title/Position:
       
*Institution Name:
*Institution Location:
       
Phone:
*Email:
       
Specialty:
(Check all that apply)
Cardiac Surgeon
Vascular Surgeon
Interventional Cardiologist
Non-Interventional Cardiologist
Interventional Radiologist
Other - Specify Below
Expertise:
(Check all that apply)

 

 
Coronary
Peripheral
CTO
Embolic Protection
Structural Heart Disease
Transcatheter Heart Valves
Heart Valve Surgery
CABG
Research
Other - Specify Below
Other:
Other:
       
Years in Practice:
Practice Type:
     
Your Medtronic Sales Representative Name(s):

CAUTION: The CoreValve ReValving® System and the Ventor EmbracerTM System are not currently available in the USA for clinical trials or for sale.
UC200904788a EN1W